car.70/il15-transduced cb-nk cells
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05092451)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Plasma Cell · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
Mechanism of action
- CD70 antigenImmunity, passive
CD70 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05703854 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2023 | University of Texas at Houston |
| NCT05092451 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1